Bastian Schilling
Overview
Explore the profile of Bastian Schilling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
9332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozistanbullu D, Wilhelm R, Reichenbach G, Doll M, Bahrami K, Zoller N, et al.
Blood Adv
. 2025 Feb;
PMID: 40020159
Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), are rare hematological malignancies with limited curative treatment options. Despite early-stage responsiveness, these malignancies often relapse in advanced...
2.
Bernhardt M, Rech A, Berthold M, Lappe M, Herbel J, Erhard F, et al.
Front Immunol
. 2025 Jan;
15():1490821.
PMID: 39835134
Background: The immunopeptidome is constantly monitored by T cells to detect foreign or aberrant HLA peptides. It is highly dynamic and reflects the current cellular state, enabling the immune system...
3.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
4.
Glutsch V, Schummer P, Goebeler M, Gesierich A, Schilling B
Front Immunol
. 2024 Dec;
15:1495004.
PMID: 39703511
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients...
5.
Kott J, Zell T, Zimmermann N, Runger A, Smit D, Abeck F, et al.
Eur J Cancer
. 2024 Dec;
214():115159.
PMID: 39642845
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through...
6.
Tarantino G, Ricker C, Wang A, Ge W, Aprati T, Huang A, et al.
Sci Adv
. 2024 Nov;
10(48):eadp4670.
PMID: 39602539
The introduction of immune checkpoint blockade (ICB) has markedly improved outcomes for advanced melanoma. However, many patients develop resistance through unknown mechanisms. While combination ICB has improved response rate and...
7.
Ozistanbullu D, Weber R, Schroder M, Kippenberger S, Kleemann J, Stege H, et al.
Healthcare (Basel)
. 2024 Sep;
12(17).
PMID: 39273714
Chemotherapy poses both physical and psychological challenges for patients, prompting many to seek answers independently through online resources. This study investigates German Google search behavior regarding chemotherapy-related terms using Google...
8.
Heinlein L, Maron R, Hekler A, Haggenmuller S, Wies C, Utikal J, et al.
Commun Med (Lond)
. 2024 Sep;
4(1):177.
PMID: 39256516
Background: Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful...
9.
Kleemann J, Schilling B
Br J Dermatol
. 2024 Aug;
191(5):654-655.
PMID: 39164211
No abstract available.
10.
Wohlfeil S, Kranzmann L, Weiss C, von Wasielewski I, Klespe K, Kahler K, et al.
Int J Cancer
. 2024 Jul;
155(10):1808-1823.
PMID: 38975881
This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received...